{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:14:11Z","timestamp":1743221651414,"version":"3.40.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.7759\/cureus.81371","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:26:48Z","timestamp":1743190008000},"source":"Crossref","is-referenced-by-count":0,"title":["First-Trimester Preeclampsia Screening During the COVID-19 Pandemic: A Quality Improvement Comparison of the National Institute for Health and Care Excellence (NICE) Guidelines vs. Simplified Fetal Medicine Foundation Algorithm"],"prefix":"10.7759","author":[{"given":"Konstantinos","family":"Malligiannis Ntalianis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Resta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama","family":"Daher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundararajah","family":"Raajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Saridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Sarafis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theocharis I","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6909.2010.01172.x","article-title":"A historical overview of preeclampsia-eclampsia","volume":"39","author":"Bell MJ","year":"2010","unstructured":"Bell MJ. A historical overview of preeclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs. 2010, 39:510-8. 10.1111\/j.1552-6909.2010.01172.x","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"ref2","unstructured":"Fetal Medicine Foundation. https.\/\/www.fetalmedicine.org\/research\/assess\/preeclampsia\/first-trimester. https:\/\/www.fetalmedicine.org\/research\/assess\/preeclampsia\/first-trimester."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis E","year":"2023","unstructured":"Dimitriadis E, Rolnik DL, Zhou W, et al.. Pre-eclampsia. Nat Rev Dis Primers. 2023, 9:8. 10.1038\/s41572-023-00417-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2014.02.001","article-title":"The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP","volume":"4","author":"Tranquilli AL","year":"2014","unstructured":"Tranquilli AL, Dekker G, Magee L, et al.. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014, 4:97-104. 10.1016\/j.preghy.2014.02.001","journal-title":"Pregnancy Hypertens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon LC","year":"2019","unstructured":"Poon LC, Shennan A, Hyett JA, et al.. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019, 145:1-33. 10.1002\/ijgo.12802","journal-title":"Int J Gynaecol Obstet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.033","article-title":"State-of-the-art diagnosis and treatment of hypertension in pregnancy","volume":"93","author":"Magee LA","year":"2018","unstructured":"Magee LA, von Dadelszen P. State-of-the-art diagnosis and treatment of hypertension in pregnancy. Mayo Clin Proc. 2018, 93:1664-77. 10.1016\/j.mayocp.2018.04.033","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002252.pub4","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos E","year":"2018","unstructured":"Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018, 10:CD002252. 10.1002\/14651858.CD002252.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13763","article-title":"A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics)","volume":"154","author":"Poon LC","year":"2021","unstructured":"Poon LC, Magee LA, Verlohren S, et al.. A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics). Int J Gynaecol Obstet. 2021, 154:3-31. 10.1002\/ijgo.13763","journal-title":"Int J Gynaecol Obstet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09499","article-title":"Estimating the cost of preeclampsia in the healthcare system: Cross-sectional study using data from SCOPE Study (Screening for pregnancy end points)","volume":"70","author":"Fox A","year":"2017","unstructured":"Fox A, McHugh S, Browne J, et al.. Estimating the cost of preeclampsia in the healthcare system: Cross-sectional study using data from SCOPE Study (Screening for pregnancy end points). Hypertension. 2017, 70:1243-9. 10.1161\/HYPERTENSIONAHA.117.09499","journal-title":"Hypertension"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003581","article-title":"Maternal and infant health care costs related to preeclampsia","volume":"134","author":"Hao J","year":"2019","unstructured":"Hao J, Hassen D, Hao Q, et al.. Maternal and infant health care costs related to preeclampsia. Obstet Gynecol. 2019, 134:1227-33. 10.1097\/AOG.0000000000003581","journal-title":"Obstet Gynecol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040022","article-title":"Costing the impact of interventions during pregnancy in the UK: A systematic review of economic evaluations","volume":"10","author":"Relph S","year":"2020","unstructured":"Relph S, Delaney L, Melaugh A, et al.. Costing the impact of interventions during pregnancy in the UK: A systematic review of economic evaluations. BMJ Open. 2020, 10:e040022. 10.1136\/bmjopen-2020-040022","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik DL","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, et al.. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017, 377:613-22. 10.1056\/NEJMoa1704559","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/uog.19039","article-title":"Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE","volume":"51","author":"Tan MY","year":"2018","unstructured":"Tan MY, Wright D, Syngelaki A, et al.. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018, 51:743-50. 10.1002\/uog.19039","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref14","unstructured":"The National Institute for Health and Care Excellence. Hypertension in pregnancy. diagnosis and management. NICE guideline [NG133]. (2019). Accessed: January 31, 2024: https:\/\/www.nice.org.uk\/guidance\/ng133."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/uog.23531","article-title":"Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13\u2009weeks' gestation: Data from EVENTS trial","volume":"57","author":"Benk\u0151 Z","year":"2021","unstructured":"Benk\u0151 Z, Wright A, Rehal A, et al.. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13\u2009weeks' gestation: Data from EVENTS trial. Ultrasound Obstet Gynecol. 2021, 57:257-65. 10.1002\/uog.23531","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/uog.22093","article-title":"Screening for pre-eclampsia at 11-13 weeks' gestation: Use of pregnancy-associated plasma protein-A, placental growth factor or both","volume":"56","author":"Mazer Zumaeta A","year":"2020","unstructured":"Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH. Screening for pre-eclampsia at 11-13 weeks' gestation: Use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020, 56:400-7. 10.1002\/uog.22093","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16477","article-title":"Aspirin should be targeted to those who need it","volume":"128","author":"Green M","year":"2021","unstructured":"Green M, Shennan A. Aspirin should be targeted to those who need it. BJOG. 2021, 128:157. 10.1111\/1471-0528.16477","journal-title":"BJOG"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17096","article-title":"Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment","volume":"129","author":"Wright D","year":"2022","unstructured":"Wright D, Tan MY, O'Gorman N, Syngelaki A, Nicolaides KH. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG. 2022, 129:1308-17. 10.1111\/1471-0528.17096","journal-title":"BJOG"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/349580-first-trimester-preeclampsia-screening-during-the-covid-19-pandemic-a-quality-improvement-comparison-of-the-national-institute-for-health-and-care-excellence-nice-guidelines-vs-simplified-fetal-medicine-foundation-algorithm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:26:51Z","timestamp":1743190011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/349580-first-trimester-preeclampsia-screening-during-the-covid-19-pandemic-a-quality-improvement-comparison-of-the-national-institute-for-health-and-care-excellence-nice-guidelines-vs-simplified-fetal-medicine-foundation-algorithm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.81371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}